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This	article	is	protected	by	copyright.	All	rights	reserved
Au
th
or
 M
an
us
cr
ip
t
3 
 
 
ABSTRACT 
Use of procurement biopsies in deceased donor kidney acceptance is controversial.  We analyzed 
Scientific Registry of Transplant Recipients data (n = 59,328 allografts, 2014-2018) to describe biopsy 
practices across US organ procurement organizations (OPOs) and examine relationships with discards, 
using hierarchical modeling to account for OPO and donor factors. Median odds ratios (MORs) provide 
medians of the odds that allografts with identical reported traits would be biopsied or discarded from 
two randomly drawn OPOs. Biopsies were obtained for 52.7% of kidneys. Biopsy use rose in a graded 
manner with kidney donor profile index (KDPI). Biopsy rates differed significantly among OPOs (22.8% to 
77.5%), even after adjustment for KDPI and other donor factors. Discard rates also varied from 6.6% to 
32.1% across OPOs. After adjustment for donor factors and OPO, biopsy was associated with more than 
3 times the likelihood of discard (adjusted odds ratio (95%LCLaOR95%UCL), 3.293.513.76). This association was 
most pronounced for low-risk (KDPI <20) kidneys (aOR, 5.456.477.69), with minimal impact at KDPI >85 
(aOR, 0.881.151.51). Adjusted MORs for kidney discard and biopsy were greatest for low-risk kidneys. 
Reducing the rate of unnecessary biopsy and improving the accuracy of pathologic findings in higher-
KDPI organs may help reduce graft discard rates.  
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INTRODUCTION 
 The ongoing shortage of organs contributes significantly to increased waitlist mortality, 
prolonged waiting times, and higher cost of care for patients with end-stage renal disease seeking 
kidney transplants.
1,2
  Although the total number of deceased donors has grown nationally (albeit 
slowly), the waiting list remains large, with nearly 100,000 candidates. Currently, only one-third of 
patients undergo transplant within 5 years of listing, and many die or become too sick before receiving 
an organ offer.
3
   Despite this critical need, and evidence that even high kidney donor risk index (KDRI) 
organs are beneficial for appropriate recipients,
4,5
 the discard rate of recovered, potentially 
transplantable kidneys increased markedly during the 2000s, and remains around 20%.
6
 Although the 
new US kidney allocation system included provisions designed to increase placement of high-risk 
organs,
3
 the high rate of kidney discard persists, thought to reflect both changing donor demographics 
and transplant program concerns about program metrics and optimizing outcomes.
7
  
 Among factors that may be associated with increased rates of kidney discard is the decision to 
perform a procurement biopsy,
8
 to assess the ͞ƋualitǇ͟ of deĐeased doŶoƌ oƌgaŶs, espeĐiallǇ those 
previously classified as from expanded criteria donors (ECD). The practice became more common after a 
1995 report by Gaber and colleagues demonstrated an increased rate of delayed graft function (DGF) 
and graft failure in patients receiving grafts with >20% glomerular sclerosis.
9
 Additional criteria, 
including the degree of inflammation, arteriolar disease, fibrosis, and tubular atrophy, are also 
considered important, but are not universally applied when determining whether or not to accept a 
donor organ.
10
 Despite widespread procurement biopsy use, concern is growing about the reliability of 
data derived from biopsy interpretation, the majority of which is based on frozen sections.  Liapis and 
Đolleagues’ ƌepoƌt fƌoŵ the BaŶff ĐoŶseŶsus conference demonstrated poor correlation in a prospective 
analysis of pathologic results from frozen section biopsy.
10
 Except for glomerular sclerosis (GS) in wedge 
biopsy, correlation between renal pathologists was poor or fair for arteriolar disease, fibrosis, and 
hyalinosis for frozen wedge or core biopsies. Furthermore, in a systematic review, Wang et al reported  
poor correlation between procurement biopsy findings and clinically important outcomes including graft 
failure, DGF, and estimated glomerular filtration rate (eGFR).
11
 Notably, routine procurement biopsies 
are not generally used outside of the US.
12
  
 Nonetheless, despite the lack of compelling data supporting use of biopsies in making decisions 
about the suitability of recovered kidneys for transplant, biopsy results are cited as the most common 
reason for organ refusal.
6
  Understanding variation in biopsy practice patterns in relationship to organ 
quality can frame subsequent efforts to reduce variability in performance of renal biopsies by 
This	article	is	protected	by	copyright.	All	rights	reserved
Au
th
or
 M
an
us
cr
ip
t
5 
 
standardizing practices that promote maximal use of available organs. The current study was designed 
to describe the national landscape of procurement biopsy practices across organ procurement 
organizations (OPOs) in the US, and to examine relationships between biopsy and kidney discard. 
  
METHODS 
Data sources 
This study used data from the Scientific Registry of Transplant Recipients (SRTR). The SRTR data system 
includes data on all donor, wait-listed candidates, and transplant recipients in the US, submitted by the 
members of the Organ Procurement and Transplantation Network (OPTN). The Health Resources and 
Services Administration (HRSA), US Department of Health and Human Services, provides oversight to the 
activities of the OPTN and SRTR contractors. We conducted a study of single kidneys recovered for the 
purpose of transplant. En-bloc and dual allografts were excluded. The data allow identification of left 
versus right kidney, pediatric en-bloc, or dual status of the organ.  Details on donor characteristics, 
including demographic information, comorbid conditions known at the time of death, donation after 
circulatory death status, and other donor-risk factors were available. Information on how OPOs handled 
the recovery of these organs, including biopsy and discard status, was also available. Baseline 
demographic information ascertained for kidney transplant recipients from OPTN included age, sex, and 
race as reported by the transplant centers. 
 
Sample and donor characteristics 
Kidney allograft characteristics were quantified using the kidney donor risk index (KDRI), which 
combines a variety of donor factors to summarize risk of graft failure after kidney transplant into a 
composite number.
13
 The KDRI expresses the relative risk of kidney graft failure for a given donor 
compared with the median kidney donor from last year; values exceeding 1 have higher expected risk 
than the median donor, and vice versa.  Elements of the KDRI score include donor age, height, weight, 
race, history of hypertension, history of diabetes, cause of death, serum creatinine, hepatitis C virus 
(HCV) status, and donation after circulatory death. The kidney donor profile index (KDPI) is a remapping 
of the KDRI onto a cumulative percentage scale, such that a donor with a KDPI of 80% has higher 
expected risk of graft failure than 80% of all kidney donors recovered last year.
14
  In addition to the 
components of KDPI, other donor factors identified in the national registry include: viral infection 
serostatus (hepatitis B core antibody status, cytomegalovirus [CMV] seropositivity, Epstein Barr Virus 
[EBV] seropositivity), cancer, smoking, substance use (alcohol, cocaine, other drugs), vasodilator use 
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prior to recovery, Public Health Service (PHS) high risk with HCV, PHS high risk without HCV, and 
pumped kidney. 
 
Outcomes: Biopsies and Discards 
Although common practice is to biopsy a single kidney and extrapolate results to the pair from each 
donor, each kidney obtained was analyzed independently for the purpose of this study. This was to 
allow for discordant decisions, as each kidney in the pair had different permutations and combinations 
of biopsy, discard, or both. Raw biopsy and discard rates were aggregated at the OPO level. 
 
Analyses 
Unadjusted Variation in Biopsy and Discard Practices across OPOs 
To visually assess unadjusted variation in biopsy and discard rates across the US, the observed 
proportion of deceased donor kidneys that were biopsied and discarded at the OPO level were plotted.  
Patterns were examined overall, and for KDPI <20 and >85. National average, unadjusted discard rates 
by biopsy status, and KDPI strata were also examined. To assess the relationship between biopsy 
practice and operational efficiency, we examined associations between median cold ischemia time and 
rates of biopsy and discard across OPOs.   
 
Combined OPO and Case-Level Modeling 
Bi-level hierarchical models were constructed to adjust for clustering effects in kidney biopsies and in 
discards. Level 1 comprised donor factors, and level 2 represented the OPO. Empirical Bayes estimates 
(EBEs) provided the adjusted proportion (with 95% confidence intervals [CI]) of the outcome of interest 
(biopsy or discard), incorporating case-mix adjustment from the hierarchical model. A 95% CI for a given 
OPO’s EBE of biopsy or discard that does not include the median national rate of use indicates a practice 
that is statistically significantly different from expected considering clinical factors in the model. To 
account for clinical factors that may explain practice variation, the models also included KDPI and other 
donor factors identified in the national database. Biopsy was considered in discard models as a 
covariate. 
Heterogeneity in biopsy use and discards by OPO was quantified using median odds ratios 
(MOR). The MOR provides the median of the odds that a kidney from a donor with identical 
characteristics will undergo biopsy (or be discarded) when two OPOs are drawn at random (performed 
for all possible pairs of OPO). For example, a MOR of 1.5 means that if OPOs are selected at random 
across all OPOs, a donor with a given set of reference characteristics is, on average, 50% more likely to 
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undergo biopsy (or discard) at one of the randomly selected OPOs than at the other.
15
 In the national 
model, KDPI 20%-50% was selected as the reference. Because of the clear, strong impact of KDPI on the 
study outcome, analyses were also stratified by KDPI level (<20%, 20%-50%, 51%-85%, >85%). In the 
adjustment for donor factors, the reference case was defined as absence of other known risk factors for 
organ discard including hepatitis B core antibody, CMV antibody, EBV antibody, and prior substance use. 
The adjusted odds ratio (95% LCLaOR95% UCL) of undergoing biopsy (or discard) for a recovered kidney was 
determined for KDPI level and other donor factors, after accounting for the effect of OPO differences 
using the hierarchical model. In the discard models, average adjusted discard rates were reported as the 
probability of discard adjusted for other factors within the stratum. 
Data were analyzed using Stata 13, College Station, TX. Hierarchical logistic regression modeling 
ǁas iŶ “tata usiŶg the ͞ǆtŵelogit͟ ĐoŵŵaŶd ǁith OPO as a random intercept. The MOR was calculated 
usiŶg ͞ǆtŵƌho͟ ;third party suite) command. 
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RESULTS 
Study sample  
From December 2014 (date of the revised kidney allocation system) to August 2018, 61,902 deceased 
donor kidneys were recovered for transplant.  After excluding 2008 en-bloc and 566 dual kidneys, a final 
cohort of 59,328 donor kidneys was available for analysis (Table 1). Donated organs from all 58 OPOs 
were included. The average biopsy rate over the period of our study across all OPOs was 52.7% (n = 
31,272), varying substantially across OPOs, from 22.8% to 77.5% (Figure 1A).  Over the period studied, 
the biopsy rate increased nationally, from 51.3% in 2014-2015 to 53.1% in 2017-2018.  The average rate 
of discard was 18.4% (n = 11,538), also varying substantially, from 6.6% to 32.1%, across OPOs. The 
overall national rate of discard remained generally stable (2014, 19.2%, to 2018, 18.9%).   
 
Biopsy and discard characteristics 
The decision to perform a biopsy was strongly associated with established donor characteristics.  We 
found a 5-fold increase in unadjusted biopsy rates from the lowest to highest strata of KDPI (Figure 2; 
Table 1).  In the lowest-risk group (KDPI <20), 19% of kidneys were biopsied.  By comparison, 95% of 
KDPI >85 kidneys were biopsied.  Other donor characteristics not included in the KDPI that were 
associated with higher biopsy rates included seropositivity for hepatitis B core, CMV, or EBV; history of 
cancer; smoking; substance use (alcohol, cocaine, other drugs); need for vasodilators, PHS high risk with 
HVC seropositivity, PHS high risk without HCV, and subsequent pulsatile perfusion.  
Rates of biopsy and kidney discard varied significantly between OPOs. Variation in biopsy 
frequency was greatest for kidneys with KDPI <20 (1.6% to 62.5%) and less for KDPI >85 kidneys (58.3% 
to 100%) (Figure 1B). As expected, the unadjusted rate of kidney discard was positively correlated with 
KDPI regardless of biopsy (Figure 2).  The unadjusted discard rate was 19-fold higher (66.2% vs. 3.8%) for 
higher-risk (KDPI >85) than for low-risk (KDPI <20) kidneys. Discard rates varied widely by OPO within 
KDPI strata; some OPOs discarded only 6.8% of high-KDPI (>85) organs while others discarded 90.9% 
(Figure 1C). 
The rate of biopsy was strongly correlated with median cold ischemia time at OPOs (Figure 3A).  
For each 10.7% increase in the rate of kidney biopsy, median cold ischemia time at the OPO increased by 
1 hour (P<.001). However, there was no significant correlation between median cold ischemia time and 
discard rate (p=0.12) (Figure 3B).   
 
Risk-adjusted assessment of the decision to perform a biopsy 
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In a hierarchical analysis adjusted for KDPI, other donor factors, and OPO, increasing KDPI level was 
strongly associated with procurement kidney biopsy. For example, compared with the reference group 
(KDPI 21-50), the adjusted odds of a biopsy were 78% lower (aOR, 0.210.220.23) for low-risk kidneys (KDPI 
<20) and 21-fold higher (aOR, 18.8821.3624.16) for higher-risk (KDPI >85) kidneys (Table 2). Other factors 
associated with high biopsy rates in the multivariate analysis included known history of drug, alcohol, or 
smoking use; prior history of cancer; hepatitis B core antibody positivity, and non-HCV-positive PHS 
status. In contrast, use of vasodilator therapy prior to recovery (12.1% of all donors) was associated with 
an 11% reduced risk of biopsy. 
 
Factors associated with increased discard rates 
Similar trends were noted when examining the relationship of discard with donor factors (Table 2).  
Compared with the reference group (KDPI 21-50), low-risk kidneys (KDPI <20) were 52% less likely to be 
discarded (aOR, 0.440.480.53). High-risk kidneys (KDPI >85) were 11-fold more likely to be discarded (aOR 
10.3111.1812.12). Other donor factors associated with increased risk of discard were a history of smoking 
(aOR, 1.271.341.42), cancer (aOR, 1.04 1.161.30), and PHS increased risk with HCV seropositivity (aOR 
4.084.535.03).  
 
Relationship between kidney biopsy and organ discard 
Procurement biopsy significantly increased the odds of kidney discard. Even after adjustment for KDPI 
and other donor factors, biopsy was associated with 3.5-fold (aOR, 3.29 3.513.76) increased odds of discard. 
When stratified by KDPI level, biopsy (vs. no biopsy) was associated with an increased rate of discard at 
each level (Figure 4).  However, this effect was most pronounced for KDPI <20 kidneys (aOR, 5.466.477.69) 
versus KDPI >85 kidneys (aOR, 0.881.151.51). The association of biopsy rate and discard rate remained 
stable over the course of this analysis.  
 
Variation in OPO Biopsy and Discard Practice 
OPO-level practice patterns had a significant impact on the variability in biopsy rates nationally.  In a null 
model clustering for OPO without adjusting donor characteristics, the MOR for biopsy performance was 
1.57 (Table 3). The addition of all donor-level factors increased the MOR from 1.57 to 1.94, suggesting 
that variation in biopsy rate among OPOs was not explained by differences in donor characteristics. 
Assessment of the measures of heterogeneity by KDPI demonstrated that variation was highest among 
kidneys with KDPI >85 (MOR = 2.58) (Figure 5). However, even among low-risk kidneys, there was 
significant adjusted variation in biopsy use (MOR = 1.99). Together, these data indicate significant 
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unexplained variability in OPO biopsy practice following adjustment for multiple known donor risk 
characteristics.  
These data also confirm the marked differences in risk-adjusted kidney discard rates between OPOs. 
In a null model clustering for OPO and without donor factors, the MOR for discard was 1.34 (Table 3). 
This value did not change with addition of donor factors, suggesting that OPO-level practice patterns 
and not donor characteristics were the major drivers of variation. The impact of biopsy practice on the 
adjusted risk of discard differed for lower- and higher-risk kidneys (Table 4; Figure 6). For KDPI 0-20 
kidneys, the MOR increased from 1.31 to 1.65 when a biopsy was performed.  Conversely, for higher-risk 
kidneys (KDPI >85), the MOR decreased with biopsy from 1.98 when no biopsy was performed to 1.74, 
suggesting less variation across OPO discard rates among biopsied organs, and that variation in discard 
rates is heavily influenced by OPO practices, organ quality, and the decision to perform a biopsy.  
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DISCUSSION 
The decision to perform a biopsy at the time of deceased donor kidney recovery is highly 
variable among OPOs, ranging from 23% to 78% of organs recovered for transplant.  Clearly, a portion of 
this disparity is driven by differences in donor characteristics, as KDPI and other donor factors correlated 
highly with the decision to perform a biopsy.  However, even within equivalent KDPI strata, we found 
marked variation in the decision to perform a biopsy. This difference in practice patterns reflects 
decisions made by OPOs and their associated transplant programs. Significant variation was also noted 
in discard rates nationally, with rates nearly 5-fold higher in high-discard regions. The association 
between biopsy and discard was strongest for low-risk kidneys (KDPI <20%) and weakest for the highest-
KDPI organs.  Overall, kidney biopsy was associated with 3.5-times the likelihood of discard after 
controlling for other donor characteristics, indicating its importance in influencing choices regarding 
organ acceptance. Increased biopsy rates were also associated with markedly greater median cold 
ischemia times.  However, there was no association between median cold ischemia time and discard 
rate.   
The relationship between preimplantation (or time-zero) kidney biopsy results and long-term 
allograft outcomes has been evaluated in a variety of retrospective single-center and registry studies.  
Wang et al evaluated 18 studies examining the association of GS and graft failure, including both 
procurement and post-reperfusion biopsies, which were evaluated as frozen sections or subsequently 
on permanent paraffin fixed slides.  In the largest study examined in the systematic review, Bajwa 
examined 12,129 patients in the OPTN database and found that graft survival was reduced by 5% at 5-
year decrements for grafts with >5% compared with <5% GS (P <0.001).
16
  However, further increases in 
GS above 5% did not predict worse outcome, including for grafts with >20% GS. Reports by Edwards et 
al. and Sung et al. using US transplant registry data  found that GS >20% was not an independent risk 
factor for graft failure for ECD organs.
17,18
 No large studies have ĐoŶfiƌŵed Gaďeƌ’s eaƌlǇ ƌepoƌt 
correlating GS and DGF.
9
  Furthermore, the systemic review suggested that association of GS and graft 
function have been conflicting; two studies demonstrated lower GFR with increasing GS, while three 
studies failed to demonstrate this effect.
11
   
The association between other pathologic findings and kidney transplant outcomes is also 
conflicting. In their systematic review, Wang et al reported that only 50% of studies demonstrated an 
association between arteriolar hyalinosis or arterial sclerosis and graft failure rates.
11
  Biopsy findings 
were associated with reduced eGFR at 1 year in patients with severe arteriolar hyalinosis, sclerosis, or 
both, but not with graft failure. There was little to no correlation between tubulointerstitial disease and 
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graft failure, DGF, or eGFR. While Hall et al demonstrated that the risk of DGF was increased in kidneys 
with acute tubular necrosis (1.231.592.06), this finding was limited to kidneys from donors after circulatory 
death and did not appear associated with decrements in long-term outcome.
19,20
 
To address the limitations inherent in procurement biopsy results, multiple scoring systems have 
been developed, which combine various pathological findings (with or without additional donor factors) 
to assess the likelihood of early graft failure.
11
  In their systemic review, Wang et al reported that only 
half of the fifteen studies examined demonstrated an association between biopsy scores and graft 
failure rates and graft function.  In 2004, Howie et al reported retrospectively assessed donor 
morphology for 500 allografts and developed an index of chronic injury.
21
  The index was strongly 
correlated with donor age, and, after adjustment for age, only an index of 40% or greater (<2% of all 
kidneys) was associated with worse outcome.  The Maryland Aggregate Pathology Index (MAPI) was 
published in 2014 using contemporary analysis of wedge biopsies.
22
 The score combines GS, arterial-
wall-to-lumen ratio, scar/fibrosis in at least 10 tubules, and arteriolar hyalinosis.  Increasing scores were 
associated with similar 1-year but reduced 3-year survival (low MAPI, 84.3%; intermediate MAPI, 56.5%; 
high MAPI, 50%; P <0.0001), a finding that was replicated at a second unaffiliated center.  However, only 
5% of allografts had a high MAPI score. The impact of MAPI score was found to be independent of age, 
ECD classification, and high terminal creatinine.  To support the value of procurement biopsy in high-risk 
kidneys, the authors point out that up to 20% of high-KDPI kidneys have a low MAPI score and would be 
expected to produce good outcomes.  
 Logistical and technical factors appear to contribute to the poor reliability of kidney allograft 
biopsy results.  Deceased donor recovery often occurs at remote hospitals during off hours, and frozen 
section interpretation may be performed by pathologists without subspecialty training in renal 
pathology.  However, interrater reliability is limited even among experts. In their seminal publication on 
the Banff Histopathological Consensus Criteria for Pre-implantation Kidney Biopsies, Liapis et al reported 
the interrater reliability for a sample of 19 pre-implantation biopsies (frozen and permanent) reviewed 
by 32 trained pathologists.
10
  In frozen section core biopsies, the interclass correlation coefficient (ICC) 
was less than 0.4 for all characteristics including GS (>0.75 is considered good). The ICC for interstitial 
fibrosis, arteriolar hyalinosis, and tubular injury were all less than 0.1.  In the wedge frozen section, only 
the ICC for GS was greater than 0.6, and scores for interstitial fibrosis, inflammation, arterial hyalinosis, 
and tubular injury were all fair to poor (ICC <0.5).  Given that these biopsies were reviewed by trained 
pathologists without time pressure, real-world reliability is highly likely to be similar or worse. In 
addition, obtaining a biopsy appears to increase cold ischemia times for transplanted organs. Because 
longer cold ischemia times have well-established associations with higher rates of delayed graft 
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function, in addition to affecting the likelihood of discard, obtaining an unnecessary biopsy may 
potentially harm outcomes for organs that are used for transplant.  
 Among the limitations of all biopsy studies is the inherent bias resulting from discarding organs 
with biopsy results that were believed to be associated with poor outcomes.  The outcome of these 
grafts is, generally, unknown, and therefore the predictive power of the scoring systems in identifying 
at-risk organs may actually be greater. Unique among these reports is that by De Vusser, outlining the 
Leuven index, which was described for 548 transplant recipients with renal biopsy specimens that were 
not used to determine transplant suitability, and were divided into a development and validation 
cohort.
23
 Using logistic regression analysis, the authors combined pathologic score for interstitial 
fiďƌosis/tuďulaƌ atƌophǇ aĐĐoƌdiŶg to the BaŶff’Ϭϳ ĐlassifiĐatioŶ, peƌĐeŶtage GS, and donor age.  A 
Leuven score >47 had an 85% specificity and 81% sensitivity for graft failure within 5 years. The authors 
further validated the score comparing frozen sections, demonstrating that the results were highly 
correlated (r = 0.99, P <0.0001).  Despite the apparent predictive value of the Leuven score, its utility in 
identifying allografts that should be discarded is limited.  Hall et al described a prospective study 
examining Leuven score, KDPI, organ discard, and graft failure in a US population of donors.
19
  Kidney 
biopsy was performed according to standard practice and varied from 16% to 87% across the five OPOs 
in the study. Leuven score and KDPI were tightly correlated (rho = 0.726, P <0.0001). Among 1,729 
organs selected for biopsy, 34% were eventually discarded.  There was no difference between KDPI and 
Leuven score in the area under the curve (AUC) (0.72) for predicting discard, although the correlation 
between discard and score was stronger for Leuven score.  Among transplanted kidneys, the AUCs for 
models predicting graft failure were modest and similar (0.62 and 0.61), suggesting that neither score 
provides a highly accurate assessment of graft function. In models including both scores, the Leuven 
score was no longer statistically significant after adjusting for KDPI. Neither scoring system accurately 
predicted DGF (AUC 0.5 and 0.53).  The authors conclude that neither KDPI nor Leuven score is 
sufficiently accurate to dictate organ discard, particularly in light of data suggesting that even very 
͞ŵaƌgiŶal͟ kidŶeǇs pƌoǀide sigŶifiĐaŶt ďeŶefit for appropriately selected candidates.5  However, it is not 
possible to know how the organs that were discarded ͞foƌ Đause͟ ǁould haǀe peƌfoƌŵed iŶ this aŶalǇsis 
if they had been transplanted.  
 Data from the current study address, in part, the ongoing issue of confounding by indication for 
biopsy.  Nationally, we demonstrate that kidneys with largely similar clinical and laboratory indications 
are biopsied at different rates on the basis of OPO and center practice. These data confirm that the 
decision to biopsy significantly increases the risk-adjusted rate of discard for all organs with KDPI <85.  
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Importantly, for organs with a KDPI >85, we found less variation in biopsy rates and aORs for discard 
related to biopsy (aOR, 0.91.21.5).  
The demonstration of variation in biopsy rates due to underlying clinical differences has led to 
efforts by the transplant community to standardize biopsy use and reduce use for low-risk kidneys, as 
the biopsy does not appear to add substantially to clinical information.  For high-KDPI organs, the 
transplant community should consider options to increase the reliability of biopsy findings.  These 
strategies include use of wedge biopsies for frozen section (based on the Banff recommendations), 
telepathology solutions to provide whole-slide imaging to a core group of trained pathologists who can 
provide real-time morphometric analysis, and allocation of kidneys with higher-risk biopsy findings to 
appropriately selected patients in transplant programs willing to use them, potentially in the context of 
dual organ transplant.  
 This study has important limitations. First, these data are retrospective and it is likely that some 
lower-risk kidneys underwent biopsy for specific clinical indications not included in the KDPI (e.g., acute 
kidney injury), which would be expected to increase discard.  However, the marked variation in biopsy 
use in this population across OPOs suggests that OPO and program preferences rather than clinical 
indications largely drive these decisions.  Notably, whether to biopsy organs is a joint decision of the 
OPO and the transplant program, and there is no clear way to discriminate decisions at the transplant 
program level with the available data. Second, we studied only the decision to biopsy; the detailed 
pathologic findings obtained as a result were not examined in this study.  However, given low ICCs and 
poor correlation of biopsy findings and outcomes, it is not clear that these data would substantially 
improve the precision of this analysis.  Third, our study was performed just after implementation of the 
revised kidney allocation system, which included provisions intended to improve use of high-risk organs. 
However, as noted, the impact of biopsy on discard rates did not decrease over time, suggesting that the 
change in allocation system did not diminish the significance of the effects described here. Finally, we 
did not examine organ outcomes by biopsy status in the current study, and therefore determination of 
the percentages of organs discarded appropriately requires ongoing investigation.  
 In conclusion, despite 20 years of data demonstrating that biopsies performed at the time of 
kidney recovery provide limited insight regarding the eventual outcome of renal allografts, more than 
50% of organs are still biopsied. This decision is highly associated with kidney discard rates, and may not 
significantly enhance information on outcomes beyond that available using clinical criteria (e.g., age, 
KDPI).  As per a recent report from a National Kidney Foundation consensus conference, efforts to 
decrease kidney discards may be strengthened by developing standards for biopsy use that could be 
informed by a randomized trial to help define the benefits and harms of procurement biopsies.
24
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of evidence to guide appropriate biopsy use, along with development of strategies to improve the 
quality of kidneys at higher risk for discard (intervention research), motivate acceptance, and expedite 
placement, are vital priorities to reduce unnecessary discard and increase access to transplant for 
patients in need.  
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FIGURE LEGENDS 
Figure 1. National US deceased donor kidney biopsy and discard rates across OPOs (December 2014-
August 2018), (A) overall and at (B) KDPI <20 and (C) >85. Each bar represents one of the 58 US OPOs.  
KDPI-stratified displays are sorted in the same order. National average unadjusted biopsy rate with KDPI 
<20 and >85: 17.0% and 95.5%; respectively. National average unadjusted discard rate with KDPI <20 
and >85: 3.5% and 64.7%; respectively. KDPI, kidney donor profile index; OPO, organ procurement 
organization. 
Figure 2. Unadjusted national kidney discard rates, by biopsy status and KDPI strata. KDPI, kidney donor 
profile index.  
Figure 3. Relationships of cold ischemia times with biopsy and discard rates across OPOs. 
Figure 4. Adjusted relationships of biopsy with discard, across KDPI strata. KDPI, kidney donor profile 
index 
Figure 5. Empirical Bayes estimates for likelihood of kidney biopsy across OPOs by KDPI strata.  KDPI-
stratified models and include adjustment for additional donor factors in the registry. The red bar 
demonstrates the national average rate of biopsy, adjusted for donor factors in the model. Each red dot 
represents adjusted biopsy rate at one OPO, and the blue bars reflect 95% CIs for use at the OPO 
determined by empirical Bayes estimates adjusting for OPO and donor factors; exclusion of the national 
average by a 95% CI reflects adjusted biopsy rates significantly above or below the national average. The 
reference donor is defined by the absence of the included donor factors (i.e., hepatitis B core antibody 
negative, cytomegalovirus negative, Epstein Barr virus negative, no substance use). CI, confidence 
interval; KDPI, kidney donor profile index; MOR, median odds ratio; OPO, organ procurement 
organization. 
Figure 6. Empirical Bayes estimates for discard rates across OPOs by KDPI strata and biopsy performance 
status: (A) with biopsy; (B) without biopsy. KDPI-stratified models and include adjustment for additional 
donor factors in the registry. The red bar demonstrates the national average rate of biopsy adjusted for 
donor factors in the model. Each red dot represents adjusted discard rate at one OPO, and the blue bars 
reflect 95% CIs for use at the OPO determined by empirical Bayes estimates adjusting for KDPI and OPO; 
exclusion of the national average by a 95% CI reflects adjusted discards rates use significantly above or 
below the national average. The reference donor is defined by the absence of the included donor factors 
(i.e., hepatitis B core antibody negative, cytomegalovirus negative, Epstein Barr virus negative, no 
substance use). CI, confidence interval; KDPI, kidney donor profile index; MOR, median odds ratio; OPO, 
organ procurement organization. 
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Table 1.  Unadjusted frequencies of biopsies and discards among deceased donor kidneys procured for 
transplant in the US, 2014-2018 (n = 59,328) 
  
Kidneys in Each 
Factor Level 
(n = 59,328) 
Biopsy %   
(n = 31,272) 
Discard %  
(n = 11,538) 
KDPI levels, %  ΐ ǂ 
    <20  18543 18.7 3.8 
    20-50 18353 49.0 11.4 
    51-60 5442 72.5 21.3 
    61-70 4829 80.0 27.2 
    71-85  6669 87.2 39.6 
    >85 5492 94.5 66.2 
Other donor factors    
Hepatitis B core antibody 
positive 
2427 73.1ǂ 34.9ǂ 
CMV positive 36074 54.6ǂ 20.9ǂ 
EBV IgG positive 53037 ϱϯ.ϴǂ 19.9ǂ 
Cancer 2003 73.8ǂ 35.7ǂ 
Smoking 11920 73.7ǂ 30.8ǂ 
Alcohol use 11215 62.1ǂ 20.1 
Cocaine use 5621 48.6ǂ 15.8ǂ 
Other drug use 26392 47.1ǂ 15.8ǂ 
Vasodilators use 7201 53.1 19.3 
PHS with HCV seropositive 2614 ϰϳ.ϰǂ ϯϳ.ϴǂ 
PHS without HCV seropositive 11320 ϰϲ.Ϯǂ ϭϯ.Ϯǂ 
Pump kidney 20150 ϲϲ.ϴǂ ϭϱ.ϰǂ 
Percentages reflect the proportions of kidneys from donors with a given clinical trait (e.g., specified KDPI 
level) that were biopsied and discarded, respectively (i.e., row percentages). Donor factors included in the 
computation of KDPI include: age, height, weight, race, history of hypertension, history of diabetes, cause of 
death, serum creatinine, HCV status, and donation after circulatory death. CMV, cytomegalovirus; EBV, 
Epstein Barr virus; HCV, hepatitis C virus; KDPI, kidney donor profile index; PHS, Public Health Service. 
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Table 2.  Associations of KDPI and other donor factors with likelihood of kidney biopsy and discard in a 
multi-level model also adjusted for OPO 
 
P-values: * p<0.05 –Ϭ.ϬϬϮ; Ώ p=Ϭ.ϬϬϭ –Ϭ.ϬϬϬϮ;  ΐ p<Ϭ.ϬϬϬϭ 
The reference KDPI level is 20%-50%. The representative donor is defined by the absence of all the 
donor factors identified in the registry (i.e., hepatitis B core antibody negative, CMV negative, EBV 
negative, no substance use). CMV, cytomegalovirus; EBV, Epstein Barr virus; HCV, hepatitis C virus; KDPI, 
kidney donor profile index; OPO, organ procurement organization; PHS, Public Health Service. 
 
 
Donor Characteristics 
Biopsy 
aOR (95% CI) 
Discard 
aOR (95% CI) 
Biopsy performed N/A 3.51 (3.29-3.76)ǂ 
KDPI levels, %   
    <20  0.22 (0.21-0.23Ϳǂ 0.48 (0.44-0.53)ǂ 
    20-50 Reference Reference 
    51-60 2.90 (2.70-ϯ.ϭϭͿǂ 1.73 (1.59-ϭ.ϴϴͿǂ 
    61-70 4.52 (4.17-ϰ.ϴϵͿǂ 2.32 (2.13-Ϯ.ϱϮͿǂ 
    71-85  8.15 (7.51-ϴ.ϴϱͿǂ 3.96 (3.68-ϰ.ϮϲͿǂ 
    >85 21.36 (18.88-Ϯϰ.ϭϲͿǂ 11.18 (10.31-ϭϮ.ϭϮͿǂ 
Other donor factors   
Hepatitis B core antibody positive 1.18 (1.06-1.32)* 1.04 (0.94-1.15) 
CMV positive 0.97 (0.93-1.02) 1.04 (0.99-1.09) 
EBV IgG positive 1.42 (1.31-ϭ.ϱϰͿǂ 0.92 (0.83-1.02) 
Cancer 1.18 (1.04-1.33)* 1.16 (1.04-1.30)* 
Smoking 1.65 (1.57-ϭ.ϳϱͿǂ 1.34 (1.27-ϭ.ϰϮͿǂ 
Alcohol  use 1.33 (1.26-ϭ.ϰϬͿǂ 0.89 (0.83-Ϭ.ϵϰͿǂ 
Cocaine use 0.96 (0.90-1.04) 0.76 (0.70-0.8ϰͿǂ 
Other drug use 1.06 (1.02-1.11)* 0.95 (0.90-1.01) 
Vasodilators use 0.89 (0.83-Ϭ.ϵϲͿƚ 0.96 (0.88-1.04) 
PHS with HCV seropositive 0.61 (0.55-Ϭ.ϲϳͿǂ 4.53 (4.08-ϱ.ϬϯͿǂ 
PHS without HCV seropositive 1.19 (1.12-ϭ.ϮϱͿǂ 1.14 (1.06-ϭ.ϮϮͿƚ 
Pump Kidney N/A 0.47 (0.44-Ϭ.ϱϬͿǂ 
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Table 3. OPO level measures of heterogeneity in biopsy and discard practices, with and without 
adjustment for donor factors  
 
 
 
 
 
 
 
 
Models are adjusted for KDPI and other donor factors in the registry. For discard, the models also 
include biopsy performance.  KDPI, kidney donor profile index; MOR, median odds ratio; OPO, organ 
procurement organization. 
 
 
 
 
 
  Biopsy Discard 
MOR, null model 1.57 1.34 
MOR adjusted for KDPI 1.91 1.35 
MOR adjusted for KDPI + other donor factors 1.94 1.34 
MOR adjusted for KDPI + other donor factors + 
performance of biopsy 
NA 1.36 
No. of OPOs significantly above reference 
probability before adjustment (null model) 
21 15 
No. of OPOs significantly above reference 
probability after adjustment  
24 18 
No. of OPOs significantly below reference 
probability before adjustment (null model) 
23 14 
No. of OPOs significantly below reference 
probability after adjustment 
23 11 
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Table 4. Adjusted variation in OPO discard rate by KDPI levels, A) among biopsied kidneys and B) among 
kidneys that were not biopsied 
A. Biopsied 
 
 
B. Not biopsied 
 
KDPI, kidney donor profile index; MOR, median odds ratio; OPO, organ procurement organization. 
 
 
 
 
 
  
No. of OPOs 
significantly above 
reference probability 
No. of OPOs significantly 
below reference 
probability 
Population averaged 
predicted discard rate 
MOR 
KDPI Levels, %     
     <20 6 1 8.4 1.65 
     20-50 6 3 19.9 1.38 
     51-85 10 7 40.7 1.40 
     >85 10 7 75.2 1.74 
  No. of OPOs 
significantly above 
reference probability 
No. of OPOs significantly 
below reference 
probability 
Population averaged 
predicted discard Rate 
MOR 
KDPI Levels, %     
     <20 1 0 1.5 1.31 
     20-50 5 1 4.1 1.46 
     51-85 5 4 18.2 1.65 
     >85 10 1 67.2 1.98 
This	article	is	protected	by	copyright.	All	rights	reserved
Au
th
or
 M
an
us
cr
ip
t
